Adult Immunization

Karl Evans R. Henson, MD, FPCP

Section of Infectious Diseases, UP-PGH

Objectives

- At the end of the lecture, the student should be able to
 - Discuss essential concepts on immunization and its classifications
 - Recognize the different adverse reactions, indications, and contraindications to vaccination
 - Determine an immunization plan for adults

Outline

- Immunization and the Immune System
- General Principles of Immunization
 - General Vaccination RUles
 - Adverse Reactions
 - Contraindications
- 2018 Adult Immunization Schedule

The Immune System

Innate Immune System

- Anatomic barriers
- Physiologic barriers
- Complement pathway
- Pattern recognition receptors (PRRs)
- Mononuclear phagocytes
- Granulocytes

Adaptive Immune System

- T cells (cell-mediated)
- B cells (humoral or Abmediated)

Types of Immunization



Types of Vaccines

| Туре | Vaccines |
|-------------------------------------|---|
| Live, attenuated | MMR, varicella, influenza (nasal spray), rotavirus, zoster/shingles (Zostavax/ZVL), yellow fever, oral polio; BCG |
| Inactivated/killed | Polio (IPV), influenza (IM), Hepatitis A, rabies; Japanese B encephalitis |
| Toxoid | Diphtheria, tetanus (part of DTaP) |
| Subunit/ recombinant | Hepatitis B, pertussis (part of DTaP), PPSV-23, meningococcal, HPV, shingles (Shingrix/RZV) |
| Conjugate (special type of subunit) | Hib, PCV-13 |

General Vaccination Rules

- There are NO contraindications to the simultaneous administration of any vaccine.
- Spacing of vaccine combinations not given simultaneously
 - Two live injected at least 4 weeks apart
 - All other vaccines no minimum interval
- Spacing of live vaccine and blood products (Ig or plasma)
 - If live vaccine given first, wait at least 2 weeks before giving Ab
 - If blood product is given first, give MMR/varicella at least 3 months after; HZ and yellow fever may be given at any time

General Vaccination Rules

- Dosing intervals of the same vaccine
 - Vaccines should NOT be administered at intervals LESS than the recommended minimum or earlier than the minimum ages (except measles outbreak and impending travel)
 - Increasing the interval between doses does NOT diminish effectiveness
 - It is NOT necessary to restart the series of any vaccine due to extended intervals between doses

Adverse Reactions

- Adverse events may be true vaccine reactions or coincidental events/human or program error
- Local reactions:
 - Pain, redness, swelling at injection site
 - Common with inactivated vaccines, usually mild or selflimited
- Systemic reactions:
 - Fever, malaise, headache
 - Nonspecific, may not be related to vaccine
- True allergic reactions to vaccine or vaccine components are rare

Contraindications and Precautions

Contraindications and Precautions

| Condition | Live | Inactivated | | |
|-----------------------|------|-------------|--|--|
| Allergy to vaccine | С | С | | |
| Encephalopathy | С | С | | |
| Pregnancy | С | V* | | |
| Immmunosuppresion | С | V | | |
| Severe Illness | Р | Р | | |
| Recent blood products | P** | V | | |

C-contraindication P- precaution V- vaccinate if indicated *except HPV ; administer Tdap preferably second or third trimester **MMR and varicella-containing, except zoster and yellow fever vaccine

Invalid Contraindications to Vaccination

- mild illness
- disease exposure or convalescence
- antibiotic therapy
- pregnancy in the household
- Breastfeeding
- allergies to products in the vaccine
- premature birth
- family history unrelated to immunosuppression
- need for TB skin testing
- need for multiple vaccines
- minor illness- low grade fever, upper respiratory tract infection, otitis media
- mild diarrhea

2018 Immunization Schedule

Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2018

This figure should be reviewed with the accompanying footnotes. This figure and the footnotes describe indications for which vaccines, if not previously administered, should be administered unless noted otherwise.

| Vaccine | 19–21 years | 22–26 years | 27–49 years | 50–64 years | ≥65 years | | | |
|--------------------------------------|--|-----------------------------|-------------|-------------|----------------------|--|--|--|
| Influenza ¹ | 1 dose annually | | | | | | | |
| Tdap ² or Td ² | 1 dose Tdap, then Td booster every 10 yrs | | | | | | | |
| MMR ³ | 1 or 2 doses depending on indication (if born in 1957 or later) | | | | | | | |
| VAR ⁴ | 2 doses | | | | | | | |
| RZV ⁵ (preferred) | | | | 2 de | oses RZV (preferred) | | | |
| ZVL ⁵ | | | | | 1 dose ZVL | | | |
| HPV–Female ⁶ | 2 or 3 doses depending | on age at series initiation | | | | | | |
| HPV–Male ⁶ | 2 or 3 doses depending | on age at series initiation | | | | | | |
| PCV13 ⁷ | 1 d <mark>ose</mark> | | | | | | | |
| PPSV237 | 1 or 2 doses depending on indication 1 dose | | | | | | | |
| НерА ⁸ | 2 or 3 doses depending on vaccine | | | | | | | |
| HepB ⁹ | 3 doses | | | | | | | |
| MenACWY ¹⁰ | 1 or 2 doses depending on indication, then booster every 5 yrs if risk remains | | | | | | | |
| MenB ¹⁰ | 2 or 3 doses depending on vaccine | | | | | | | |
| Hib ¹¹ | 1 or 3 doses depending on indication | | | | | | | |



Recommended for adults who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection

Recommended for adults with other indications

Figure 2. Recommended immunization schedule for adults aged 19 years or older by medical condition and other indications, United States, 2018

This figure should be reviewed with the accompanying footnotes. This figure and the footnotes describe indications for which vaccines, if not previously administered, should be administered unless noted otherwise.

| | | Immuno- compromised (excluding HIV | HIV in CD4+ (cells/) | fection count IL) ^{3-7,9-10} | Asplenia, complement | End-stage renal disease, on | Heart or lung disease, | Chronic liver | | Health care | Men who have sex |
|--------------------------------------|--|---|--|---|---------------------------------|--------------------------------|---------------------------------------|------------------------|-------------|----------------------------|---------------------------|
| Vaccine | Pregnancy ¹⁻⁶ | infection) ^{3-7,11} | <200 | ≥200 | deficiencies ^{7,10,11} | hemodialysis ^{7,9} | alcoholism ⁷ | disease ⁷⁻⁹ | Diabetes7,9 | personnel ^{3,4,9} | with men ^{6,6,9} |
| Influenza ¹ | | | | | | 1 dose annu | ally | | | | |
| Tdap ² or Td ² | 1 dose Tdap each pregnancy | se ach 1 dose Tdap, then Td booster every 10 yrs ancy | | | | | | | | | |
| MMR ³ | cont | contraindicated 1 or 2 doses depending on indication | | | | | | | | | |
| VAR ⁴ | cont | raindicated | | | | 2 do | ses | | | | |
| RZV ^s (preferred) | | | | | 2 de | oses RZV at age 🤉 | ≥50 yrs (prefer | red) | | | |
| ZVL ^s | cont | raindicated | | | | 1 dose ZVL at | age ≥60 yrs | | | | |
| HPV-Female ⁶ | | 3 doses through age 26 yrs 2 or 3 doses through age 26 yrs | | | | j | | | | | |
| HPV-Male ⁶ | | 3 doses through age 26 yrs 2 or 3 doses through age 21 yrs 20 | | | | | 2 or 3 doses through age 26 yrs | | | | |
| PCV13 ⁷ | 1 dose | | | | | | | | | | |
| PPSV23 ⁷ | 1, 2, or 3 doses depending on indication | | | | | | | | | | |
| HepA ⁸ | | 2 or 3 doses depending on vaccine | | | | | | | | | |
| HepB ⁹ | | | | | | | 3 d | oses | | | |
| MenACWY ¹⁰ | | | 1 0 | or 2 dose | es depending on | indication , then | booster every | / 5 yrs if risk re | mains | | |
| MenB ¹⁰ | | 2 or 3 doses depending on vaccine | | | | | | | | | |
| Hib11 | | 3 doses HSCT recipients only | 3 doses HSCT recipients only 1 dose | | | | | | | | |



Recommended for adults who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection

Recommended for adults with other indications

Vaccine

Туре

Route

Schedule

Other comments

Influenza

In the PHL, inactivated

IM

Annual

Southern hemisphere, available as tri- and quadrivalent

TDAP

Mixed (T/D toxoid, aP subunit)

IM

1 dose TDaP, TD every 10y thereafter

Give to adults who haven't received TT/D/aP as an adult or child (11-12y), or can't remember

MMR

Live, attenuated SC

1-2 doses, at least 28 days apart

Evidence of immunity: born before 1957 (except HCW), documentation of MMR, antibody titers; For women, give 3-months before planned conception and they should not get pregnant until 3 months after

Varicella

Live, attenuated

SC

2 doses, at least 28 days apart

Evidence of immunity: Documentation of 2 doses VAR at least 4wks apart, antibody titers, verification of disease by HC provider

Herpes zoster

LIVE/ZOSTAVAX

Live, attenuated (ZVL)

SC

One dose

Regardless of past episode of varicella, HZ

RECOMBINANT/SHINGRIX

| Recombinant (RZV) |
|---|
| IM |
| 0, 2-6 months |
| Now the vaccine of choice for HZ; Give regardless of past episode of varicella, HZ, or receipt of ZVL; must give 2 months after ZVL |

Human Papilloma Virus

| Female | Male |
|---|---|
| Recombinant (4 or 9 strains) | Recombinant (4 or 9 strains) |
| IM | IM |
| For adults: 3 doses, 0/1-2/6 months | For adults: 3 doses, 0/1-2/6 months |
| Ages 15-26; 2 doses for ages 9-14 HPV 6,11,16,18 | Ages 15-26*; 2 doses for ages 9-14 HPV 6,11,16,18, 31, 33, 45,52, 58 |

Pneumococcal

| PCV-13 | PPSV-23 |
|---|---|
| Recombinant (4 or 9 strains) | Recombinant (4 or 9 strains) |
| IM | IM |
| For adults: 3 doses, 0/1-2/6 months | For adults: 3 doses, 0/1-2/6 months |
| Ages 15-26; 2 doses for ages 9-14 HPV 6,11,16,18 | Ages 15-26*; 2 doses for ages 9-14 HPV 6,11,16,18, 31, 33, 45,52, 58 |

Figure 3. Recommended pneumococcal vaccination schedule and intervals, by age, health condition, and other risks.



Hepatitis A

Inactivated

IM

2 doses, 0-6 months

Also available in combo with Hep B (Twinrix), given 0-1-6 months

Hepatitis B

Recombinant; HBsAg expressed in yeast, purified and given as vaccine

IM

3 doses; 0-1-6 months

Accelerated schedule: 0-1-2-12 months

For combo Hep A/B: 3 doses, 0-1-6 months

Meningococcal ACWY

Conjugated (the polysaccharide MPSV4 no longer recommended)

IM

2 doses, at least 28 days apart

Evidence of immunity: Documentation of 2 doses VAR at least 4wks apart, antibody titers, verification of disease by HC provider

Meningococcal B

Recombinant

IM

2 doses, at least 28 days apart

Evidence of immunity: Documentation of 2 doses VAR at least 4wks apart, antibody titers, verification of disease by HC provider

Haemophilus influenza type B

| Conjugated |
|--|
| IM |
| Dosing depends on indication, 1-2 doses |
| Pre-splenectomy: 1 dose at least 14 days prior Post-HSCT: 3-dose series, doses 4 wks apart, starting 6-12 months after successful transplant |

Global Immunzation: Current Status Goal: Polio eradication



© WHO. All rights reserved

A successful eradication program meets the following conditions:

- Infection must be limited to humans, with no animal reservoir
- In viral infections, there must be only one or a few strains of the virus, with constant antigenic properties
- The virus must not persist in the infected host
- There must be an effective vaccine

Download "CDC Vaccine Schedules" free for iOS and Android devices.



Product Specs

Version: 5.0.2

Requirements: Requires iOS 8.0 or later and Android 4.0 or later; optimized for tablets and useful on smartphones.

Updates: Changes in the app are released through app updates.

Download app free for iOS



Download app free for Android



References

- Clem AS. J Global Infect Dis. 2011;3(1):73-8.
- Ada G. NEJM. 2001;345(14):1042-53.
- ACIP 2018 Adult Immunization Schedule
- PSMID/PFV Adult Immunization Recommendation 2017.
- CDC:

https://www.cdc.gov/vaccines/vpd/index.html

• WHO: <u>http://www.who.int/news-room/fact-</u> <u>sheets/detail/immunization-coverage</u>